CASE REPORT ABOUT IMMUNOTHERAPY IN MANAGEMENT OF METASTATIC RENAL CANCER: TREATMENT WITH CHECKPOINT PD-L1 AND/OR ANTI-CTLA-4 INHIBITORS

Palomino R.M.; Palomino J.M.M.; Malpartida J.M. · Revista de la Facultad de Medicina Humana (2023) · DOI: 10.25176/rfmh.v23i4.6202

Resumen

Introduction: Renal cell carcinoma (RCC) represents approximately 15%, presenting as advanced or metastatic, where surgery is not curative. The prognosis of patients with advanced or metastatic CRC can vary from a few months to a few years, depending on the clinical, pathological and radiological characteristics of the disease. Currently, anti-monoclonals are being used, which is based on immunotherapy-based as checkpoint inhibitors in the initial systemic therapy of advanced treatment of clear cell RCC. Clinical case: This research presents a clinical case where immunotherapy plays a role through the use of anti-monoclonals for the approach of a male patient with metastatic kidney disease who presents a clinical response after surgical treatment and immunotherapy for two years without evidence of oncological disease to date.

Instituciones: Universidad Peruana de Ciencias Aplicadas